This is a routine annual proxy filing. Monitor for any unexpected outcomes in the shareholder vote, though none are anticipated given the lack of dissident activity. The recent executive compensation change noted in the 8-K is the only notable event.
NVCR drugs
NVCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 21 $12.23entry
- T+1 · 7mo ago +6.46%α +5.44% · $13.02
- T+5 · 7mo ago −0.90%α −1.98% · $12.12
- T+20 · 6mo ago +42.76%α +37.85% · $17.46
- T+60 · 4mo ago +34.26%α +27.36% · $16.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NovoCure's DEFA14A filing is a definitive proxy statement for its 2026 Annual Meeting, where shareholders will vote on director elections, auditor ratification, executive compensation, and an amended incentive plan. This follows recent board changes, suggesting the vote is routine. The filing is neutral with low impact.
Key Financial Metrics
Key Facts
- Filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting.
- Shareholders will vote on 11 director nominees, auditor ratification, executive compensation, and an amended incentive plan.
- Recent 8-K filing (11 days prior) reported a compensation change for an executive officer.
- No activist campaign or dissident slate is present; this is a management solicitation.
Financial Impact
No direct financial impact from the proxy filing itself.
Risk Factors
- Low risk of shareholder revolt on any proposal, as is typical for routine management solicitations.
- Potential for minor governance concerns if any director nominee faces significant opposition, though none is indicated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001645113-26-000034 |
| Document: 0001645113-26-000034-index-headers.html | 0001645113-26-000034 |
| Document: 0001645113-26-000034-index.html | 0001645113-26-000034 |
| Document: 0001645113-26-000034.txt | 0001645113-26-000034 |
Track record
20 reports on NVCR
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +19.75% at T+20 after the Feb 27, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $11.83 to $11.30 Now $11.30 −4.48% ▼ −4.48% −2.57% vs SPY
- Nov 9, 20267d ago SC 13G/A Neutral 3/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $11.81 to $11.99 Now $11.30 −4.32% ▲ +1.52% +0.21% vs SPY
- Nov 9, 20267d ago 8-K Bearish 6/10 Entry $12.53 to $11.81 Now $11.30 +9.82% ▲ +5.75% +5.38% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $13.11 to $13.15 Now $11.30 −13.81% ▲ +0.31% +2.08% vs SPY
- Oct 1, 20266w ago 8-K Bullish 6/10 Entry $15.92 to $14.94 Now $11.30 −29.02% ▼ −6.16% −6.90% vs SPY
- Sep 9, 20269w ago 8-K Neutral 2/10 Entry $15.63 to $15.35 Now $11.30 −27.70% ▼ −1.79% −1.19% vs SPY
- Sep 1, 202610w ago 8-K Neutral 3/10 Entry $17.38 to $17.83 Now $11.30 −34.98% ▲ +2.59% +2.15% vs SPY
- Jul 23, 202616w ago 8-K Bullish 7/10 Entry $19.99 to $17.65 Now $11.30 −43.47% ▼ −11.71% −11.81% vs SPY
- Jun 30, 202619w ago 8-K Bullish 7/10 Entry $15.15 to $15.78 Now $11.30 −25.41% ▲ +4.16% +4.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers